Biofidelity Ltd, 330 Cambridge Science Park, Milton road, CB4 0WN, Cambridge, England.
BMC Med Genomics. 2022 Oct 12;15(1):215. doi: 10.1186/s12920-022-01363-0.
RNA is a critical analyte for unambiguous detection of actionable mutations used to guide treatment decisions in oncology. Currently available methods for gene fusion detection include molecular or antibody-based assays, which suffer from either being limited to single-gene targeting, lack of sensitivity, or long turnaround time. The sensitivity and predictive value of next generation sequencing DNA-based assays to detect fusions by sequencing intronic regions is variable, due to the extensive size of introns. The required depth of sequencing and input nucleic acid required can be prohibitive; in addition it is not certain that predicted gene fusions are actually expressed.
Herein we describe a method based on pyrophosphorolysis to include detection of gene fusions from RNA, with identical assay steps and conditions to detect somatic mutations in DNA [1], permitting concurrent assessment of DNA and RNA in a single instrument run.
The limit of detection was under 6 molecules/ 6 µL target volume. The workflow and instrumentation required are akin to PCR assays, and the entire assay from extracted nucleic acid to sample analysis can be completed within a single day.
RNA 是明确检测用于指导肿瘤学治疗决策的可操作突变的关键分析物。目前用于基因融合检测的方法包括分子或抗体检测方法,这些方法要么限于单基因靶向,要么灵敏度不足,要么周转时间长。由于内含子的广泛大小,基于下一代测序 DNA 检测融合通过测序内含子区域的方法的灵敏度和预测值是可变的。所需的测序深度和输入核酸可能是禁止的;此外,不能确定预测的基因融合实际上是否表达。
本文描述了一种基于焦磷酸解的方法,用于从 RNA 中检测基因融合,其与用于检测 DNA 中体细胞突变的相同的检测步骤和条件相同[1],允许在单个仪器运行中同时评估 DNA 和 RNA。
检测限低于 6 个分子/6 μL 目标体积。所需的工作流程和仪器类似于 PCR 检测方法,从提取的核酸到样品分析的整个检测过程可以在一天内完成。